Endo Unveils USP Doxycycline Injection

Endo, Inc., a versatile specialty pharmaceutical company committed to turning insights into therapies that improve lives, has announced the initiation of shipping for its doxycycline for injection, USP 100 mg/vial, an AP-rated alternative to Doxy 100.

“We are excited to offer healthcare professionals and hospital pharmacies more options to help deliver excellent patient care,” stated Scott Sims, the senior vice president and general manager of injectable solutions & generics at Endo. “Our addition of doxycycline for injection enriches our comprehensive sterile injectable product line and reinforces our status as a dependable source of aseptic medications.”

According to IQVIA, sales of doxycycline for injection 100 mg vials were about $49 million for the twelve months ending September 30, 2024.

Doxy 100 is a registered trademark of Fresenius Kabi.

Endo is a versatile specialty pharmaceutical company committed to turning innovations into therapies that enhance lives. The dedicated team members work collaboratively to create and supply these crucial medications.